Vertebral osteoporotic fractures with height loss secondary to Cushing’s disease by Nogueira, C et al.
ÓRgÃO OfiCiAL DA sOCiEDADE PORTUgUEsA DE REUMATOLOgiA
1
CARTA AO EDiTOR
1. Department of Endocrinology, Diabetes and Metabolism, 
Centro Hospitalar são João, Porto, Portugal; faculty of Medicine, 
University of Porto, Portugal
2. Department of Endocrinology, Hospital de Braga, Braga, Portugal
3. Department of Pathology, Centro Hospitalar são João, Porto,
Portugal; faculty of Medicine, University of Porto, Portugal; 
institute of Molecular Pathology and immunology at the 
University of Porto, Portugal
4. Department of neurosurgery, Centro Hospitalar são João,
Porto, Portugal
der treatment with alendronate and cholecalciferol.
Glucocorticoids (GCs) cause impaired bone forma-
tion due to direct effects both on osteoblasts and os-
teoclasts1. GCs also inhibit vitamin D action, reducing
calcium absorption from the gastrointestinal tract and
renal tubular calcium reabsorption2. The effects of GCs
on gonadotropins, growth hormone and insulin-like
growth factor-1 may also contribute to osteoporosis de-
velopment, and catabolic effects of GCs on muscle
enhance fracture risk.
Fractures are found in approximately 30-67% of pa-
tients with Cushing’s syndrome (CS)1. Trabecular bone
is more severely affected than cortical bone in GCs in-
duced osteoporosis, because of its higher turnover rate
and its greater sensitivity to GCs action3,4. Therefore,
the vertebral bodies and ribs are the typical sites of frac-
tures in CS. The European Registry on Cushing’s syn-
drome showed that, in patients with any form of CS,
men had significantly more vertebral and rib frac-
tures compared with women (52 vs.18% for vertebrae;
p<0.001 and 34 vs. 23% for ribs; p<0.05)5. Male gen-
der was found to be an important risk factor for lum-
bar osteoporosis and fractures in CD6.
Disease severity and duration seem to play a crucial
role in determining permanent damage to the spine. In
this case, surgical treatment would be indicated but the
patient refused. Some authors reported that GCs indu-
ced osteoporosis is reversible7, but recovery of bone
loss is gradual and may continue for 10 years before
BMD normalizes8. A recent study showed a significant
increase in BMD at 3 months after surgery in the lum-
bar spine in patients cured of CS due to adrenocortical
adenoma7. Another study reported that alendronate
may induce a more rapid improvement in BMD than
cortisol normalization alone, maybe by restoring the
balance between bone formation and resorption9. It is
also useful in patients with persistent postsurgical hy-
percortisolism. Since there is a substantial reduction of
bone formation, treatment with an anabolic agent that
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To the editor,
A 37-year-old man was referred to our department due
to osteoporosis complicated with vertebral and rib frac-
tures and loss of six centimeters in height within the
previous year. He also had hypertension, dyslipidemia,
and secondary infertility and he was treated with alen-
dronate and cholecalciferol. Physical examination re-
vealed a moon face, central obesity, proximal muscle
weakness, easy bruising, and kyphosis. Laboratory in-
vestigation showed ACTH dependent hypercortisolism
[24-hour urinary free cortisol: 687.3µg/day (36–137);
cortisol after a 1-mg overnight dexamethasone sup-
pression test: 39.5µg/dL (<1.8); ACTH:118pg/mL 
(< 53)]. Total testosterone was low [1.93mg/mL (2.8-
-8.0)]. Since pituitary magnetic resonance imaging sho-
wed no adenoma, he was submitted to bilateral inferior
petrosal sinus sampling, which favored Cushing’s di-
sease (CD). Dual-energy X-ray absorptiometry (DXA)
revealed osteoporosis of the lumbar spine (T-score -3.8,
Z-score -3.8) and of the left femur (T-score -3.6, Z-sco-
re -2.7). A thoracic computed tomography showed
multiple vertebral compression fractures in the thora-
cic spine and increased thoracic kyphosis (Figure 1).
After cryopreservation of gametes, the patient was
submit ted to transsphenoidal surgery and histological
findings confirmed the diagnosis. He refused surgical
treatment of vertebral fractures. DXA performed five
months after surgery showed osteoporosis of the lum-
bar spine (T-score -3.4, Z-score -3.6) and osteopenia of
the left femur (T-score -2.0, Z-score -1.9). He is still un-
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promotes bone formation and reduces vertebral and
non-vertebral fractures has also been suggested1. Teri-
paratide is indicated to increase bone mass in men with
primary or hypogonadal osteoporosis who are at high
risk for fracture10. Although its use has not been stu-
died in endogenous CS it is beneficial in patients with
exogenous GCs induced osteoporosis.
In conclusion, this case illustrates the need to con-
sider secondary causes of osteoporosis, namely Cus-
hing’s syndrome and other endocrinopathies, in a
young patient with osteoporotic fractures.
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FIGURE 1. Reconstructed sagittal (1A) and coronal (1B) CT image shows numerous compression fractures
involving the thoracic and lumbar spine, osteopenia and increased thoracic kyphosis
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